AIM IMMUNOTECH INC
AIMNYSE AMERICANTrading Snapshot
- Day Range
- $0.11 โ $0.12
- 52-Week Range
- $0.11 โ $1.82
- Volume (shares)
- 5,095
- Avg Volume (shares)
- โ
- Shares Outstanding
- 39.9M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- $88,000
- Last Q Revenue
- $26,000
- P/E Ratio
- โ
- P/S Ratio
- 48.2x
- EPS (TTM)
- $-3.93
- Dividend Yield
- โ
AIM IMMUNOTECH INC
AIMFinancial history unavailable.
About AIM IMMUNOTECH INC
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.